CA2293504A1 - Use of leptin antagonists for the treatment of diabetes - Google Patents

Use of leptin antagonists for the treatment of diabetes Download PDF

Info

Publication number
CA2293504A1
CA2293504A1 CA002293504A CA2293504A CA2293504A1 CA 2293504 A1 CA2293504 A1 CA 2293504A1 CA 002293504 A CA002293504 A CA 002293504A CA 2293504 A CA2293504 A CA 2293504A CA 2293504 A1 CA2293504 A1 CA 2293504A1
Authority
CA
Canada
Prior art keywords
leptin
treatment
insulin
mice
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002293504A
Other languages
English (en)
French (fr)
Inventor
Valur Emilsson
Michael Anthony Cawthorne
Yong-Ling Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2293504A1 publication Critical patent/CA2293504A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002293504A 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes Abandoned CA2293504A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/002240 WO1998055139A1 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Publications (1)

Publication Number Publication Date
CA2293504A1 true CA2293504A1 (en) 1998-12-10

Family

ID=8166613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002293504A Abandoned CA2293504A1 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Country Status (9)

Country Link
EP (1) EP0986397A1 (ja)
JP (1) JP2002504102A (ja)
KR (1) KR20010013414A (ja)
AU (1) AU2951797A (ja)
CA (1) CA2293504A1 (ja)
HU (1) HUP0003428A3 (ja)
IL (1) IL133136A0 (ja)
TR (1) TR199902980T2 (ja)
WO (1) WO1998055139A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
CN103897066A (zh) 2004-02-11 2014-07-02 安米林药品有限责任公司 具有可选择特性的杂合多肽
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EA011653B1 (ru) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Аналоги и гибридные полипептиды gip с избираемыми свойствами
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
TR201901299T4 (tr) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
PT3509624T (pt) 2016-09-12 2023-08-28 Amryt Pharmaceuticals Inc Métodos de deteção de anticorpos neutralizantes anti-leptina

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP0836479A2 (en) * 1995-06-30 1998-04-22 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
HUP0003428A2 (hu) 2001-05-28
AU2951797A (en) 1998-12-21
JP2002504102A (ja) 2002-02-05
KR20010013414A (ko) 2001-02-26
TR199902980T2 (xx) 2000-05-22
WO1998055139A1 (en) 1998-12-10
HUP0003428A3 (en) 2001-12-28
EP0986397A1 (en) 2000-03-22
IL133136A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
CA2293504A1 (en) Use of leptin antagonists for the treatment of diabetes
Haffner et al. The role of behavioral variables and fat patterning in explaining ethnic differences in serum lipids and lipoproteins
Larsen et al. Differential influences of peroxisome proliferator–activated receptorsγ and-α on food intake and energy homeostasis
Yip et al. Functional GIP receptors are present on adipocytes
Roman et al. Central leptin action improves skeletal muscle AKT, AMPK, and PGC1α activation by hypothalamic PI3K-dependent mechanism
Cincotta et al. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice
Caprio et al. Hyperleptinemia: an early sign of juvenile obesity. Relations to body fat depots and insulin concentrations
Caprio et al. Metabolic impact of obesity in childhood
Toste et al. Neonatal leptin treatment programmes leptin hypothalamic resistance and intermediary metabolic parameters in adult rat
Baldelli et al. Glucose homeostasis in acromegaly: effects of long‐acting somatostatin analogues treatment
Garcia-Vicente et al. Oral insulin-mimetic compounds that act independently of insulin
Bell-Anderson et al. Leptin as a potential treatment for obesity: progress to date
Henry et al. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors
US20080020974A1 (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x
Zhang et al. Aged-obese rats exhibit robust responses to a melanocortin agonist and antagonist despite leptin resistance
Wasan et al. Emerging pharmacological approaches to the treatment of obesity
US20040142868A1 (en) Method of treating liver steatosis in a mammal
Judge et al. Prolonged hyperphagia with high-fat feeding contributes to exacerbated weight gain in rats with adult-onset obesity
Baltaci et al. Pinealectomy and melatonin administration in rats: their effects on plasma leptin levels and relationship with zinc
US20040048773A1 (en) Use of leptin antagonists for the treatment of diabetes
CA2474964C (en) An insulin improving agent containing adiponectin
Liu et al. Basal and stimulated plasma leptin in diabetic subjects
Freedman et al. Effect of adrenalectomy on in vivo glucose metabolism in insulin resistant Zucker obese rats
Frittitta et al. High insulin levels do not influence PC‐1 gene expression and protein content in human muscle tissue and hepatoma cells
US20020002181A1 (en) Use of leptin antagonists for the treatment of diabetes

Legal Events

Date Code Title Description
FZDE Discontinued